Karyopharm Therapeutics Inc logo

Karyopharm Therapeutics Inc

$ 5.50 +0.2 (+3.77%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 438.94M
Enterprise V:
$ 432.02M
Volume:
1.79M
Avg Vol (2M):
2.11M
Also Trade In:
Volume:
1.79M
Market Cap $:
438.94M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.11M
Enterprise Value $:
432.02M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Karyopharm Therapeutics Inc
NAICS : 325412 SIC : 5999
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Name Current Vs Industry Vs History
Cash-To-Debt 0.95
Equity-to-Asset -0.45
Debt-to-Equity -1.55
Debt-to-EBITDA -2.44
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.38
Distress
Grey
Safe
Beneish M-Score -1.19
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 67.24
9-Day RSI 64.3
14-Day RSI 60.11
6-1 Month Momentum % -68.71
12-1 Month Momentum % -4.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.88
Quick Ratio 3.82
Cash Ratio 2.73
Days Inventory 381.16
Days Sales Outstanding 31.26
Days Payable 196.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.6

Financials (Next Earnings Date:2022-11-03 Est.)

KPTI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:KPTI

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 251.307
EPS (TTM) ($) -1.38
Beta -0.2
Volatility % 76.21
14-Day RSI 60.11
14-Day ATR ($) 0.419769
20-Day SMA ($) 4.8075
12-1 Month Momentum % -4.86
52-Week Range ($) 4 - 14.73
Shares Outstanding (Mil) 79.81

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Karyopharm Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More